10-KT: Regenerex Pharma Faces Going Concern Doubt Amidst Losses

Regenerex Pharma, Inc. reported a significant net loss for the nine months ended December 31, 2025, and faces substantial doubt about its ability to continue as a going concern, despite strategic initiatives in wound care.

Summary

• Regenerex Pharma, Inc. is a company focused on developing and marketing wound care healing products, with three core technologies for chronic, acute, and contaminated wounds.
• The company has not generated revenue and reported a net loss of $2,543,211 for the nine months ended December 31, 2025, compared to a net loss of $2,527,041 for the year ended March 31, 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to ongoing losses, negative cash flows, and negative working capital.
• Regenerex is actively seeking to raise an additional $5,000,000 by September 2026 to sustain operations until contracts begin.
• The company experienced a material loss of $399,680 due to a hacking incident on a bank account in March 2025, with $90,000 recovered through a settlement.
• Material weaknesses in internal control over financial reporting were identified, primarily due to a lack of in-house personnel with sufficient technical accounting and SEC reporting expertise.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued lack of revenue, significant net losses, substantial doubt about its ability to continue as a going concern, and material weaknesses in internal controls.

Positives

• The company possesses proprietary QBx technology for wound care, which it claims is effective in down-regulating proteases that impede healing.
• Regenerex has developed a comprehensive product portfolio including Accelerex Sterile Wound Cream, Accelerex Impregnated Sterile Wound Dressing, and Xcellderma OTC.
• Strategic initiatives include developing managed care agreements with southeastern states for Medicaid patients and prison systems, potentially representing over $100 million in annual revenue.
• Negotiations are underway with distributors in Middle Eastern and Asian countries for international expansion.
• The company has a new 2025 Equity Incentive Plan designed to attract and retain talent.
• The lease for the manufacturing facility with Woundcare Labs, LLC was terminated effective December 31, 2025, reducing future obligations.

Negatives

• The company has no revenue history and has incurred significant net losses, with a loss of $2,543,211 for the nine months ended December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The company requires significant additional financing and has no commitments for it, which could jeopardize its business plan.
• A material loss of $399,680 occurred due to a hacking incident on a bank account.
• Material weaknesses in internal control over financial reporting were identified due to insufficient accounting and SEC reporting expertise.
• The company is heavily dependent on its key personnel, and their departure could harm business operations.
• The company's securities are considered penny stocks, which may discourage tradability due to special sales practice requirements.

Risks

• The company faces competition from existing consumer product companies.
• As an emerging growth company, reduced disclosure requirements may make shares less attractive to investors.
• The company has a lack of revenue history and limited operational history.
• The company is not profitable and has no assurance of future profitability or revenue generation.
• The company will need additional financing, and there is no guarantee it will be available on acceptable terms.
• The company is not diversified and is dependent on a single business, increasing susceptibility to industry fluctuations.
• The company may issue more shares, potentially leading to a loss of control by current management and stockholders.
• The company is heavily dependent on its management team, and their inability to devote full-time attention could delay progress.

Future Outlook

The company is actively seeking to raise an additional $5,000,000 by the end of September 2026 to provide adequate cash until contracts start. Management plans to continue funding operations through additional equity issuances, debt financing, strategic licensing arrangements, and commercialization of its wound care technologies. The company expects to generate revenue from home care service providers funded by government programs and is negotiating with international distributors.

Management Comments

• Regenerex Pharma Inc. has entered a pivotal phase of strategic expansion, with multiple initiatives underway to strengthen our market position and operational capabilities.
• Our business development team has made significant progress in negotiations with our first State Medicaid program. These contracts represent substantial annual revenue.
• Management believes that the Company's unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. and global markets.
• Management believes that the Company's QBx technology will provide a distinct advantage over other companies providing services in this sector.

Industry Context

StockSavvy.ai notes that Regenerex Pharma operates in the wound care market, a sector experiencing growth driven by an aging population and increasing rates of chronic conditions like diabetes. The company's focus on a technology that down-regulates proteases to promote healing addresses a significant unmet need in chronic wound management, where conventional treatments often fail. The shift towards pay-for-performance reimbursement models in the US healthcare system, as highlighted by the Affordable Healthcare Act, creates opportunities for companies offering cost-effective and efficient solutions.

Comparison to Industry Standards

• The company claims its Wound Closure System has been shown in clinical trials to successfully close up to 95% of non-responding chronic wounds within 90 days, which it states is superior to other treatment systems in efficacy, time to closure, and price competitiveness.
• While specific competitor financial data is not provided in this filing, Regenerex's lack of revenue and significant net losses contrast sharply with established players in the wound care market who typically have substantial revenue streams and are often profitable.
• The company's reliance on an asset-light manufacturing strategy and contract manufacturing is a common approach in the pharmaceutical and medical device industries to manage capital expenditure and operational flexibility.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed against former Chief Financial Officer, Kenneth W. Perry, and Optimize Health Partners, LLC to recover funds and address matters arising from his conduct.
• The actions seek monetary damages, restitution, disgorgement, injunctive relief, costs, and other equitable remedies.

Related Party Transactions

• Asset Purchase Agreement with current CEO and former Secretary/Treasurer for intellectual property in exchange for 150,000,000 shares and contingent consideration up to $10,000,000.
• Agreement with Greenwich (entity related to a shareholder's family member) to purchase intellectual property for a $2,400,000 note payable.
• Lease agreement with Woundcare Labs, LLC (related to CEO) for a plant and equipment, which was terminated effective December 31, 2025.
• Promissory notes issued to the Company's CEO for operating expenses.
• Promissory notes issued to a related shareholder and their family members for funding.
• Agreement with Optimize Health Partners, LLC (related to former CFO) for IT systems, involving share issuance for a license, currently in dispute.

Stakeholder Impact

• Shareholders face dilution risk from potential future share issuances for capital raises or acquisitions.
• Shareholders may experience volatility in share price due to the company's financial instability and penny stock status.
• Creditors and lenders face increased risk due to the company's going concern issues and need for significant financing.
• Employees and consultants may face uncertainty regarding job security and compensation due to the company's precarious financial situation.

Next Steps

• Continue negotiations with State Medicaid programs and private insurance networks for managed care agreements.
• Pursue international expansion by negotiating with distributors in Middle Eastern and Asian countries.
• Seek additional debt and/or equity capital to launch the business and commence material operations.
• Implement enhanced internal controls and cybersecurity measures in response to the hacking incident.
• Address the identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company exhibits significant financial distress, including a lack of revenue, substantial net losses, and explicit doubt about its ability to continue as a going concern. The identified material weaknesses in internal controls and the recent hacking incident further exacerbate the risks. While there are strategic initiatives and proprietary technology, the immediate financial instability and operational challenges outweigh the potential upside, making it a high-risk investment.

Keywords

wound care, chronic wounds, diabetic ulcers, pressure ulcers, Regenerex Pharma, QBx technology, Accelerex, financial condition